LOTTE Biologics Secures First Major Commercial Deal for Songdo Plant 1

COMPANY PROFILE
  • LOTTE Biologics has signed a commercial manufacturing agreement with a global pharmaceutical company, securing the first major commercial commitment for Songdo Plant 1 ahead of its operational launch.
  • The agreement covers integrated drug substance and drug product manufacturing, with commercial production targeted to begin in 2027.

LOTTE Biologics has secured a commercial manufacturing agreement with a global pharmaceutical company, marking the first major commercial manufacturing commitment for its Songdo Plant 1 in South Korea. Under the agreement, LOTTE Biologics will provide integrated drug substance and drug product manufacturing services for key products in the customer’s portfolio, with commercial production targeted to begin in 2027.

The agreement was secured while the facility is still under development and ahead of its operational launch. Songdo Plant 1 is part of the company’s Songdo Bio Campus, which is being developed with a planned total capacity of 360,000 liters across three plants. Plant 1 will provide 120,000 liters of capacity through eight 15,000-liter stainless-steel bioreactors.

The facility is being designed with advanced production infrastructure, automation and large-scale cold-chain warehousing to support biologics manufacturing. It will complement the company’s Syracuse Bio Campus in New York, which has more than two decades of manufacturing experience and a record of supporting more than 62 regulatory approvals. The Syracuse site also recently completed an FDA inspection with zero observations.

Together, the Songdo and Syracuse facilities will form an integrated global manufacturing network. LOTTE Biologics said the network is intended to provide operational flexibility, consistent quality standards and greater supply chain resilience for pharmaceutical customers.

“The agreement demonstrates customer confidence in the company’s strategy and its plans to combine Syracuse’s manufacturing experience with Songdo’s infrastructure to support global biologics production.”

James Park, Co-CEO of LOTTE Biologics
EXCLUSIVE DOWNLOAD

Download the full CDMO Live Report for 112 pages of insights and best practices in external manufacturing.